Sepracor, Inc.
Records under this name other than the patents Sepracor, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,562,878 | Cycloalkylamines as Monoamine Reuptake Inhibitors Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 8,269,040 | Derivatives of Venlafaxine and Methods of Preparing and Using the Same Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,902,252 | Inhibitors of D-Amino Acid Oxidase Formerly held In force · High confidence | In force | High confidence | |
| US 7,718,822 | Carbamate Stereoisomer Formerly held In force · High confidence | In force | High confidence | |
| US 8,053,603 | Tetralone-Based Monoamine Reuptake Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 9,114,086 | Coated Tablets of Eszopiclone Formerly held In force · High confidence | In force | High confidence | |
| US 8,877,975 | Cycloalkylamines as Monoamine Reuptake Inhibitors Formerly held Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 8,877,755 | Dopamine-Agonist Combination Therapy For Improving Sleep Quality Formerly held Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 7,488,747 | Pyrrole and pyrazole DAAO inhibitors Term ended Term ended Jul 8, 2026 · From the USPTO record | Term ended | Term ended Jul 8, 2026 | From the USPTO record |
| US 7,465,729 | Methods of Treatment of Menopause and Perimenopause Using Eszopiclone Formerly held Term ended Term ended Apr 27, 2026 · High confidence | Term ended | Term ended Apr 27, 2026 | High confidence |